The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
Avinash Gupta
No relevant relationships to disclose
Victor Moreno
No relevant relationships to disclose
Emma Jane Dean
No relevant relationships to disclose
Yvette Drew
No relevant relationships to disclose
Shibani Nicum
No relevant relationships to disclose
Malcolm Ranson
Consultant or Advisory Role - Safety Review Panel
Ruth Plummer
No relevant relationships to disclose
Helen Swaisland
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Wendy Burke
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Peter McCormack
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Ilian Tchakov
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Mark R. Middleton
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Stanley B. Kaye
Consultant or Advisory Role - AstraZeneca; AstraZeneca
Honoraria - AstraZeneca; AstraZeneca
L Rhoda Molife
Research Funding - AstraZeneca